<DOC>
	<DOCNO>NCT00872976</DOCNO>
	<brief_summary>The purpose study determine recommend dose combination dasatinib bendamustine chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Study Dasatinib Bendamustine Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria ( Cohort # 1 ) : Diagnosis BCLL NCI criterion Require chemotherapy fully recover previous administer chemotherapy Subjects must progress , fail achieve meaningful response , relapsed/intolerant prior therapy . Failing least one purine analogue regimen Subjects receive three few prior treatment regimen ECOG status 0 2 Inclusion Criteria ( Cohort # 2 ) : If dose level + 3 reach , criterion outline Cohort # 1 , however subject history prior chemotherapy ( treatment naive ) Unwilling unable use acceptable method avoid pregnancy Uncontrolled significant cardiovascular disease , include prolonged QTc interval History significant bleeding disorder , unrelated CLL Prior concurrent malignancy Drugs generally accept risk cause Torsades de Pointes Autoimmune hemolytic anemia require therapy transfusion support Autoimmune thrombocytopenia require steroid therapy transfusion support Richter 's Syndrome Transformation prolymphocytic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>